Novartis gets US Menveo extension in young children but not infants
This article was originally published in Scrip
Executive Summary
Novartis has secured approval from the US FDA to extend the use of its quadrivalent meningococcal conjugate vaccine, Menveo, down to children aged two to 10 years old. The initial US approval, granted in March 2010, was for adolescents and adults aged 11 to 55 years.